Amendments to the Claims

Please amend Claims 1 and 3. Please add new Claims 4-10. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A method for treating a TNF-mediated neurodegenerative disease in a human, comprising administering to said human at least one anti-TNF monoclonal antibody, or a TNF binding fragment thereof.

2. (Original) A method of Claim 1, wherein the TNF-mediated neurodegenerative disease is multiple sclerosis.

3. (Currently amended) A method of Claim 1, wherein the TNF-mediated neurodegenerative disease is selected from AIDS dementia complex, a demyelinating disease, multiple sclerosis, acute transverse myelitis, an extrapyramidal disorder, a cerebellar disorder, a lesion of the corticospinal system, a disorder of the basal ganglia, a hyperkinetic movement disorder, Huntington's Chorea, senile chorea, a drug-induced movement disorder, a hypokinetic movement disorder, Parkinson's disease, progressive supranucleo palsy, a structural lesion of the cerebellum, a spinocerebellar degeneration, spinal ataxia, Friedreich's ataxia, a cerebellar cortical degeneration, a multiple systems degeneration, a systemic disorder, Refsum's disease, abetalipoprotemia, ataxia telangiectasia, a mitochondrial multi-system disorder, a demyelinating core disorder, acute transverse myelitis, a disorder of the motor unit, a neurogenic muscular atrophy, anterior horn cell degeneration, amyotrophic lateral sclerosis, infantile spinal muscular atrophy, juvenile spinal muscular atrophy, Alzheimer's disease, Down's Syndrome, a diffuse Lewy body disease, senile dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, subacute sclerosing panencephalitis, Hallerrorden-Spatz disease or dementia pugilistica.

4. (New) The method of Claim 1, wherein the anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.

5. (New) The method of Claim 1, wherein the antibody is a chimeric antibody, comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, wherein the anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.

6. (New) The method of Claim 5, wherein the chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5 and an IgG1 human constant region.

7. (New) The method of Claim 1, comprising administering to the human a single or divided 0.1 - 100 mg/kg dose of the anti-TNF antibody for a sufficient period of time to treat the TNF-mediated neurodegenerative disease, wherein the anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.

8. (New) The method of Claim 1, wherein the antibody neutralizes human TNF-α *in vivo*.

9. (New) The method of Claim 1, wherein the antibody is produced by a recombinant method or a chemical synthesis method.

10. (New) The method of Claim 1, wherein the antibody is produced by a method using a hybridoma.